|
**Overview**: Allergy House Dust Mites Panel**Introduction**: The Allergy House Dust Mites Panel is a diagnostic tool designed to screen for dust mite allergies using serum samples. In India, house dust mites (Dermatophagoides pteronyssinus and farinae) are the dominant indoor allergen, with sensitization rates of 47-93 percent in allergic rhinitis and asthma patients. High humidity, overcrowding, poor ventilation in urban slums and rural homes, and monsoons favor mite proliferation. Symptoms include persistent rhinitis, nocturnal asthma, coughing, and eye irritation. High morbidity from underdiagnosis in low-SES households, limited testing, and overlap with viral infections. Per immunology practices aligned with ICMR guidelines, the test employs immunoassay for detailed parameter analysis over 1-2 days with high sensitivity/specificity, valuable for identifying mite triggers in perennial cases. This diagnostic falls under allergy screening and targets individuals with suspected dust mite allergies, addressing accurate detection to guide environmental control and therapy. With morbidity elevated due to underdiagnosis in densely populated areas, the test supports public health efforts by enabling precise identification, facilitating management, and reducing chronic symptoms. Its serum-based approach ensures reliable detection.**Other Names**: Dust Mites Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Expanded with specific IgE testing; in India, prominence due to dust mite dominance in indoor allergen profiles.**Purpose**: The test screens for 2 parameters including D. pteronyssinus IgE to guide dust mite allergy assessment, identify triggers, inform treatment.**Test Parameters**: 1. Dermatophagoides pteronyssinus IgE, 2. Dermatophagoides farinae IgE.**Pretest Condition**: No fasting required; patients should report persistent rhinitis or nocturnal asthma symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on home environment (dust, bedding, humidity), symptom patterns, family atopy.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated dust mite allergies including chronic respiratory issues, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible dust mite triggers, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: Allergists or pulmonologists should be consulted for case management, environmental control planning.**Additional Supporting Tests**: Home dust sampling or environmental assessment for confirmation.**Test Limitations**: The test may produce false negatives in low exposure or false positives in sensitization without clinical disease, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Indian Journal of Allergy Asthma Immunology 2024, Dust Mite Studies India 2023. |
